Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285103 | 0.82 | LMNA (0.50) | EPHX1EPHX2KDM1ARIPK1GAA | |
| SCHEMBL28278914 | 0.80 | GAA (0.51) | EPHX1EPHX2RIPK1GAATDP1 | |
| SCHEMBL12436970 | 0.80 | EPHX1 (0.43) | EPHX1EPHX2KDM1ARIPK1PDK2 | |
| Hydrochloric Acid SCHEMBL977934 | 0.80 | LMNA (0.49) | EPHX1EPHX2KDM1ARIPK1GAA | |
| SCHEMBL7608711 | 0.77 | EPHX1 (0.41) | EPHX1EPHX2KDM1ARIPK1PDK2 | |
| SCHEMBL5758149 | 0.77 | EPHX1 (0.46) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL3835392 | 0.76 | EPHX1 (0.43) | EPHX1EPHX2KDM1ARIPK1CYP2C19 | |
| SCHEMBL19195033 | 0.76 | EPHX2 (0.43) | EPHX2 | |
| SCHEMBL8486161 | 0.75 | EPHX1 (0.45) | EPHX1EPHX2KDM1ARIPK1CYP2C19 | |
| SCHEMBL4131266 | 0.75 | EPHX1 (0.45) | EPHX1EPHX2KDM1ARIPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION | 2019-07-11 | — | — | US | disclosed |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-6602885-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20030004185-A1 | Piperidine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-01-02 | — | — | US | disclosed |
| US-6387930-B1 | ANTIARTHRITIC AGENTS; ANTIALLERGENS; SKIN DISORDERS; INFLAMMATORY BOWEL DISORDERS | SCHERING CORPORATION | 2002-05-14 | — | — | US | disclosed |
| EP-1175402-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000066559-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | EPHX1 709/4885EPHX2 1352/4885KDM1A 489/4885 |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | EPHX1 173/4885EPHX2 780/4885KDM1A 1196/4885 |
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | EPHX1 1059/4885EPHX2 611/4885KDM1A 271/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | EPHX1 709/4885EPHX2 1352/4885KDM1A 489/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | EPHX1 709/4885EPHX2 1352/4885KDM1A 489/4885 |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | EPHX1 173/4885EPHX2 780/4885KDM1A 1196/4885 |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | EPHX1 173/4885EPHX2 780/4885KDM1A 1196/4885 |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | EPHX1 1059/4885EPHX2 611/4885KDM1A 271/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | EPHX1 709/4885EPHX2 1352/4885KDM1A 489/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | EPHX1 709/4885EPHX2 1352/4885KDM1A 489/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | EPHX1 709/4885EPHX2 1352/4885KDM1A 489/4885 |
| US-20030004185-A1 | Piperidine derivatives useful as CCR5 antagonists | CCR5, CCR1, CCR2 | EPHX1 2674/4885EPHX2 1754/4885KDM1A 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.